# EDGAR Filing Document

**Accession Number:** 0001658247
**File Stem:** 0000000000-23-001500
**Filing Date:** 2023-2
**Character Count:** 7859
**Document Hash:** 6c51501c747102252142e75a2a837790
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-23-001500.hdr.sgml**: 20230502

**ACCESSION NUMBER**: 0000000000-23-001500

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20230214

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Crinetics Pharmaceuticals, Inc.
- **CENTRAL INDEX KEY:** 0001658247
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 263744114
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD

**BUSINESS ADDRESS:**
- **STREET 1:** 10222 BARNES CANYON ROAD, BLDG. #2
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121
- **BUSINESS PHONE:** 858-450-6464

**MAIL ADDRESS:**
- **STREET 1:** 10222 BARNES CANYON ROAD, BLDG. #2
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121
**PUBLIC REFERENCE ACCESSION NUMBER**: 0000950170-22-005050

## Text-Extract

```

United States securities and exchange commission logo

                             February 14, 2023

       Marc J.S. Wilson
       Chief Financial Officer
       Crinetics Pharmaceuticals, Inc.
       10222 Barnes Canyon Road
       Bldg. #2
       San Diego, California 92121

                                                        Re: Crinetics
Pharmaceuticals, Inc.
                                                            Form 10-K for
Fiscal Year Ended December 31, 2021
                                                            Filed March 30,
2022
                                                            File No. 001-38583

       Dear Marc J.S. Wilson:

               We have reviewed your January 19, 2023 response to our comment
letter and have the
       following comment. In our comment, we may ask you to provide us with
information so we may
       better understand your disclosure.

              Please respond to the comment within ten business days by
providing the requested
       information or advise us as soon as possible when you will respond. If
you do not believe our
       comment applies to your facts and circumstances, please tell us why in
your response.

            After reviewing your response to the comment, we may have
additional
       comments. Unless we note otherwise, our references to prior comments are
to comments in our
       December 20, 2022 letter.

       Form 10-K for the Fiscal Year Ended December 31, 2021

       Notes to Consolidated Financial Statements
       8. Radionetics Oncology, Inc., page F-16

   1.                                                   We note your response
to prior comment two. Please address the following as it relates to
                                                        your determination that
you do not have the power to direct the activities that most impact
                                                        Radionetics' economic
performance:

                                                              You disclose that
no party has power over Radionetics' key activities - including
                                                            research and
development (R&D), financing decisions and determining strategic
                                                            direction. Explain
whether there is a contractual mechanism in place to resolve
                                                            disputes in the
event that a majority decision cannot be reached with respect to one of
 Marc J.S. Wilson
Crinetics Pharmaceuticals, Inc.
February 14, 2023
Page 2
              Radionetic's key activities.
                Address the following with respect to power over R&D
activities:
                o  Describe to us the composition of Radionetics' R&D
committee.
                o  Tell us whether any of Radionetics' R&D activities are
performed by Crinetics
                   employees.
                o  Describe to us any related party or agent relationships
among Crinetics, 5AM
                   Ventures, Frazier Healthcare Partners and/or the independent
board member.
                o  Tell us whether others apart from Crinetics are capable of
performing the R&D
                   activities, and explain to us whether reliance on Crinetics
provides a substantial
                   barrier to other board members exercising their rights.
                Provide us with a copy of the Collaboration and License
Agreement and any other
              relevant Radionetics' agreements in order to assist us with our
analysis.

       You may contact Ibolya Ignat at 202-551-3636 or Angela Connell at
202-551-3426 with
any questions.

FirstName LastNameMarc J.S. Wilson                              Sincerely,
Comapany NameCrinetics Pharmaceuticals, Inc.
                                                                Division of
Corporation Finance
February 14, 2023 Page 2                                        Office of Life
Sciences
FirstName LastName

```

### Attached PDF Documents

**Attachment 1:** `filename1`

![img-0.jpeg](img-0.jpeg)

DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

February 14, 2023

Marc J.S. Wilson
Chief Financial Officer
Crinetics Pharmaceuticals, Inc.
10222 Barnes Canyon Road
Bldg. #2
San Diego, California 92121

**Re: Crinetics Pharmaceuticals, Inc.**
**Form 10-K for Fiscal Year Ended December 31, 2021**
**Filed March 30, 2022**
**File No. 001-38583**

Dear Marc J.S. Wilson:

We have reviewed your January 19, 2023 response to our comment letter and have the following comment. In our comment, we may ask you to provide us with information so we may better understand your disclosure.

Please respond to the comment within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe our comment applies to your facts and circumstances, please tell us why in your response.

After reviewing your response to the comment, we may have additional comments. Unless we note otherwise, our references to prior comments are to comments in our December 20, 2022 letter.

Form 10-K for the Fiscal Year Ended December 31, 2021

Notes to Consolidated Financial Statements

8. Radionetics Oncology, Inc., page F-16

1. We note your response to prior comment two. Please address the following as it relates to your determination that you do not have the power to direct the activities that most impact Radionetics' economic performance:

- You disclose that no party has power over Radionetics' key activities - including research and development (R&D), financing decisions and determining strategic direction. Explain whether there is a contractual mechanism in place to resolve disputes in the event that a majority decision cannot be reached with respect to one of

Marc J.S. Wilson
Crinetics Pharmaceuticals, Inc.
February 14, 2023
Page 2

Radionetic's key activities.

- Address the following with respect to power over R&D activities:
  - Describe to us the composition of Radionetics' R&D committee.
  - Tell us whether any of Radionetics' R&D activities are performed by Crinetics employees.
  - Describe to us any related party or agent relationships among Crinetics, 5AM Ventures, Frazier Healthcare Partners and/or the independent board member.
  - Tell us whether others apart from Crinetics are capable of performing the R&D activities, and explain to us whether reliance on Crinetics provides a substantial barrier to other board members exercising their rights.
- Provide us with a copy of the Collaboration and License Agreement and any other relevant Radionetics' agreements in order to assist us with our analysis.

You may contact Ibolya Ignat at 202-551-3636 or Angela Connell at 202-551-3426 with any questions.

Sincerely,

Division of Corporation Finance
Office of Life Sciences